噬菌体抗体库构建技术在疾病防治中的应用

噬菌体抗体库技术(phage antibody library)是近年发展的一项分子生物学新技术,近年来越来越多的学者利用这项技术获得目标抗体以应用于医疗制药及安全检测等多个领域.噬菌体抗体库技术的发展和应用,为抗体技术领域带来了巨大的变化,极大地推动了各种性能优良基因工程抗体的开发和应用.针对噬菌体抗体库构建的原理、方法、构建过程中所需考虑的因素以及在不同领域的应用作了综述.     

噬菌体抗体库技术在肿瘤治疗中的研究进展及应用北大核心CSCD

肿瘤是严重威胁人类健康的疾病。目前肿瘤治疗策略以手术切除、放化疗、靶向治疗和免疫治疗为主。单克隆抗体药物因具备高效性和低毒性等特点,逐渐成为肿瘤临床治疗中不可或缺的药物类型。噬菌体抗体库技术(phage antibody library technology,PALT)是一种新型的单克隆抗体制备技术,其将免疫球蛋白可变区VH(variable region of heavy chain)/VL(variable region of light chain)基因重组后整合在噬菌体载体上,并以融合蛋白的形式将抗体表达到噬菌体表面,从而获得多样性抗体库。抗体库经过“吸附-洗脱-扩增”过程即可筛选获得到特异结合抗原的抗体分子及其基因序列。PALT具有抗体生产周期短、抗体结构可塑性强、抗体产量大、多样性高和可直接生产人源化抗体等优点,已应用于乳腺癌、胃癌、肺癌和肝癌等肿瘤标志物的筛选和抗体药物的制备等领域。文中综述了PALT在肿瘤治疗中的研究进展及应用。     

鼠源抗B型肉毒毒素Fab抗体库的构建及初步筛选

目的:应用重组噬菌体抗体库技术制备抗B型肉毒毒素Fab抗体。方法:用重组B型肉毒毒素重链C端片段(BoNTB/Hc)免疫BALB/c小鼠,从其脾淋巴细胞扩增免疫球蛋白Fd段和κ链基因,克隆至表达载体pComb3中,并将抗体Fab段表达于噬菌体表面,建立容量为5.96×106cfu的噬菌体抗体库。以BoNTB/Hc为抗原对所建抗体库进行4轮亲和筛选,获得与B型肉毒毒素特异性结合的克隆,并进行序列测定。结果:构建了抗B型肉毒毒素Fab抗体库,筛选出特异性克隆1个。结论:从鼠源噬菌体免疫抗体库中初步获得了特异性抗B型肉毒毒素的Fab抗体。     

利用重组系统构建大容量噬菌体抗体库

噬菌体抗体库技术是获得人源抗体的重要方法,此文探讨大容量天然噬菌体抗体库在筛选人源抗体中的实际应用价值。从正常人外周血分离淋巴细胞,通过基因工程方法获得抗体基因并且构建到含有重组位点的载体pDF中获得初级噬菌体抗体库,初级库在重组系统中重组之后获得了容量为9×1010的天然Fab噬菌体抗体库,通过序列测定和重组蛋白筛选来对抗体库的质量进行初步鉴定。对随机挑取的96个克隆测序序列分析表明各种型别比例基本合适;用四种抗原筛选有明显的富集,并且获得了针对其中一种抗原的阳性抗体克隆。     

抗大肠癌噬菌体单链抗体的筛选及初步鉴定

 应用 3种方法 (肿瘤细胞膜表面和胞内、裸鼠体内和组织切片 ) ,从全人源化的抗大肠癌噬菌体初级抗体库中筛选肿瘤特异性的噬菌体单链抗体 (Sc Fv) .在肿瘤细胞经过 3轮亲和选择 ,回收结合胞膜和内化进入胞内的噬菌体 ,得到抗肿瘤噬菌体单链抗体的富集倍数为 430倍 ;荷瘤裸鼠体内注入初级抗体库后 ,在不同时刻点处死裸鼠 ,回收肿瘤组织内的噬菌体 ,其回收率在 2 4 h时最高 ;初级抗体库与大肠癌组织切片亲和选择后 ,从冰冻组织切片上比从石蜡组织切片上回收得到的噬菌体高出约 1 .6倍 .从上述方法挑选单克隆 ,经 ELISA筛选抗大肠癌阳性噬菌体克隆株 ,分离得到 5个对大肠癌细胞反应较好的单克隆噬菌体单链抗体 .进一步用细胞 ELISA检测对各种肿瘤细胞的特异性反应 ,其中 4个对大肠癌细胞有很好的特异性 ,1个克隆对所有肿瘤细胞均有反应 .因此 ,3种方法用于筛选抗大肠癌噬菌体初级抗体库是有效的 ,具有推广和应用价值 .     

噬菌体单链抗体文库的构建及筛选

噬菌体抗体是继多克隆抗体、单克隆抗体之后兴起的第3代基因工程抗体.噬菌体抗体库技术是抗体基因文库技术和噬菌体表面展示技术相结合形成的一项新技术与方法,在生物科学领域极具潜力.现主要就近年来该技术在抗体基因扩增、抗体库的构建、筛选方法等方面的进展进行综述.     

抗病毒噬菌体抗体库研究进展

噬菌体抗体库技术是基于噬菌体表面展示技术发展起来的一项基因抗体工程新技术.它将含亿万种基因的抗体可变区基因库转化成展示在噬菌体表面的蛋白库,不仅使对于具备所需属性的单克隆抗体筛选能更方便、快速、高效地在体外进行,还开辟了单克隆抗体人源化的新途径,揭开了人类单克隆抗体生产的历史新篇章.本文综述了近年来针对各种病毒的噬菌体抗体库的构建、筛选方法以及其在各种病毒性疾病研究中的最新进展.     

噬菌体抗体库研究进展

治疗性抗体的发展经历了异源抗体、人源化抗体和人源性抗体几个阶段。目前,人源性抗体是治疗性抗体发展的主要方向,而噬菌体抗体库技术的出现为人源性抗体的制备提供了良好的技术平台,并且逐渐成为目前获得人源性抗体的主要手段之一。噬菌体抗体库技术是20世纪90年代初期抗体工程领域的一项重大进展,它是噬菌体展示和抗体库2种技术的集成,目前广泛应用于生物医学领域。本文对该技术的原理、类型、特点及研究进展进行了综述。     

纳米抗体技术及其在疾病诊断和治疗中的应用

单克隆抗体具有特异性结合抗原的能力,已被广泛应用于疾病诊断及治疗领域.但因单克隆抗体的组织渗透能力较差、体内的保留时间较长以及制备过程繁琐,从而限制了其在临床中的应用.自1993年首次报道在骆驼体内天然存在的单链抗体(HCAb)以来,由于其可变区间VHH(纳米抗体)具有体积小、溶解度高、特异性强以及可在细菌中大量表达等优点,较之传统单克隆抗体,VHH在疾病的诊断治疗及药物开发等医学领域具有更广阔的应用前景.本文综述了:纳米抗体的骨架区及互补决定区与传统抗体重链相应区间的结构比较;纳米抗体库的构建以及运用噬菌体展示技术对VHH库的筛选;纳米抗体技术在疾病诊断中的应用及其用于分子显像的优势,以及纳米抗体作为抗肿瘤免疫偶联物的靶向组分在癌症治疗领域中的最新进展.     

一种从抗狂犬病病毒噬菌体抗体库中筛选和验证中和抗体的方法

目的建立一种从噬菌体库抗体库中高效筛选和验证抗狂犬病病毒中和抗体的方法。方法①定性分析:从经过灭活的CVS-11筛选噬菌体抗体库中挑取单克隆于96孔板中培养,制备噬菌体抗体,取培养上清进行快速荧光灶抑制试验(rapid fluorescent focus inhibition test, RFFIT),选择可明显抑制病毒感染的克隆测序,获得具有中和活性的抗体可变区序列;②定量分析:挑选有中和活性的克隆,重新制备噬菌体抗体颗粒,纯化后进行RFFIT分析;扩增抗体可变区基因,构建真核瞬时表达质粒。瞬转HEK-293 EBNA1细胞,培养上清经Mabselect SuRe亲和纯化后测定抗体比活。结果定性分析获得的噬菌体抗体颗粒与全分子抗体体外中和活性显著相关;剔除低活性序列后,活性高于0.5 IU/mL的噬菌体抗体颗粒与其全分子抗体体外中和活性之间无显著相关;所有纯化后噬菌体抗体颗粒活性>0.5 IU/mL的序列其全分子抗体体外中和活性均>500 IU/mg。结论构建了一种从抗狂犬病病毒噬菌体库中高效筛选、验证中和抗体的方法。     

Peptide-displaying phage technology in glycobiology

Phage display technology is an emerging drug discovery tool. Using that approach, short peptides that mimic part of a carbohydrate's conformation are selected by screening a peptide-displaying phage library with anti-carbohydrate antibodies. Chemically synthesized peptides with an identified sequence have been used as an alternative ligand to carbohydrate-binding proteins. These peptides represent research tools useful to assay the activities of glycosyltransferases and/or sulfotransferases or to inhibit the carbohydrate-dependent binding of proteins in vitro and in vivo. Peptides can also serve as immunogens to raise anti-carbohydrate antibodies in vivo in animals. Phage display has also been used in single-chain antibody technology by inserting an immunoglobulin's variable region sequence into the phage. A single-chain antibody library can then be screened with a carbohydrate antigen as the target, resulting in a recombinant anti-carbohydrate antibody with high affinity to the antigen. This review provides examples of successful applications of peptide-displaying phage technology to glycobiology. Such an approach should benefit translational research by supplying carbohydrate-mimetic peptides and carbohydrate-binding polypeptides.     

Phage display: Concept,innovations, applications and future

Phage display is the technology that allows expression of exogenous (poly)peptides on the surface of phage particles. The concept is simple in principle: a library of phage particles expressing a wide diversity of peptides is used to select those that bind the desired target. The filamentous phage M13 is the most commonly used vector to create random peptide display libraries. Several methods including recombinant techniques have been developed to increase the diversity of the library. On the other extreme, libraries with various biases can be created for specific purposes. For instance, when the sequence of the peptide that binds the target is known, its affinity and selectivity can be increased by screening libraries created with limited mutagenesis of the peptide. Phage libraries are screened for binding to synthetic or native targets. The initial screening of library by basic biopanning has been extended to column chromatography including negative screening and competition between selected phage clones to identify high affinity ligands with greater target specificity. The rapid isolation of specific ligands by phage display is advantageous in many applications including selection of inhibitors for the active and allosteric sites of the enzymes, receptor agonists and antagonists, and G-protein binding modulatory peptides. Phage display has been used in epitope mapping and analysis of protein-protein interactions. The specific ligands isolated from phage libraries can be used in therapeutic target validation, drug design and vaccine development. Phage display can also be used in conjunction with other methods. The past innovations and those to come promise a bright future for this field.     

中国医学科学院北京协和医学院放射医学研究所天津市分子核医学重点实验室

血液肿瘤即造血系统的恶性肿瘤,是一种严重危害公共健康的疾病。目前,血液肿瘤诊断治疗的最理想方法就是分子特异性诊断和靶向治疗,但该方法面临的最大困难就是分子靶点的选择。噬菌体展示技术是近十年发展起来的一种新的生物学技术,具有高通量筛选、模拟天然表位、易于纯化、将蛋白功能与编码基因相统一等优点,广泛应用于功能性蛋白质和多肽的筛选、蛋白质间的识别与相互作用、抗原表位的鉴定、基因工程抗体的筛选等多个分子生物学领域,非常适于理想靶点的选择。目前,噬菌体文库技术在血液肿瘤诊治中的应用主要集中在噬菌体抗体文库和噬菌体随机肽库上。本文就噬菌体展示技术在血液肿瘤诊断治疗中的研究成果做一总结分析,并对该技术在这一领域的应用前景进行展望。     

噬菌体抗体库技术的研究进展及应用

噬菌体抗体库技术是继噬菌体展示技术发展而来的一项基因抗体工程新技术。它可将含不同物种全部抗体可变区基因的基因库转化成展示在噬菌体表面的蛋白库,不仅使单克隆抗体的生产更方便、快速、高效地在体外进行,还开辟了单克隆抗体人源化的新途径,促进了人类单克隆抗体生产的发展。就近年来噬菌体抗体库技术的基因来源、发展关键及抗体应用的研究作一综述。     

The phage display technique: advantages and recent patents

Phage display technology has advanced considerably since its creation, and the number of research projects using this technique is constantly increasing, generating numerous antibody and antigen libraries. These libraries, besides expediting library screening, improving selection methods and allowing evaluation of novel applications, have great potential for the development of new vaccines, drugs and diagnosis tests. Consequently, patent registries for the protection of these sequences are essential.     

Screening of tumor-targeting peptides for diagnosis and therapy through phage display technology

Phage display technology was introduced by G. Smith in 1985, which is highly effective in the selection of affinity peptides from a library containing billions of display peptides. The obtained peptides show potential efficacy in the development of further clinical applications, especially in tumor treatment. In this review, the basic principles, limits, developments of phage display technology and peptide libraries are introduced. Following that, the amino acid sequence of tumor target peptides for hematological and other systems are discussed. Finally, the application of target peptides in the design of imaging probes and the development of target peptide drugs for diagnosis and therapy are noted.     

Panning and identification of a colon tumor binding peptide from a phage display peptide library

Tumor-targeting therapy can be an efficacious way to cure a malignant tumor in clinical trials. Phage display is a molecular diversity technology that allows the presentation of a large number of peptides or proteins on the surface of filamentous phage for various applications. In this study, we report on using phage display to generate peptide libraries that bind to colon cancer tissues. To accomplish this, we developed a screening protocol that contained 3 rounds of in vitro positive panning on colon cancer cells (SW480) and 2 rounds of subtractive screening in vitro on normal human intestinal epithelial cells with a phage display-7 peptide library. After several rounds of panning, both phage titer and recovery efficiency were significantly improved. Through a cell-based enzyme-linked immunosorbent assay, immunofluorescence, in vivo binding assay, immunocytochemical staining, and immunohistochemical staining, peptide CP15 (VHLGYAT) was demonstrated to be the most effective peptide in targeting tumor cells (SW480 and HT29 cells) and tumor tissues but not the normal human intestinal epithelial cells and control colon tissue. These studies suggest that peptide CP15 may be a promising lead candidate in the development of a useful colon tumor diagnostic and targeted drug delivery agent.     

噬菌体展示技术及其在肿瘤研究中的应用

噬菌体表面展示技术是一项特异性多肽或蛋白的筛选技术,它将随机序列的多肽或蛋白片段与噬菌体衣壳蛋白融合表达而呈现于病毒表面,被展示的多肽能保持相对独立的空间结构,使其能够与配体作用而达到模仿性筛选特异性分子表位,从而提供了高通量高效率的筛选系统。近年来噬菌体展示技术已广泛应用于肿瘤抗原抗体库的建立、单克隆抗体制备、多肽筛选、疫苗研制、肿瘤相关抗原筛选和抗原表位研究、药物设计、癌症检测和诊断、基因治疗及细胞信号转导研究等。就近年来噬菌体展示技术在肿瘤相关研究中的运用作以综述。     

噬菌体展示技术研究进展

噬菌体表面展示技术是一种将外源蛋白或抗体可变区与噬菌体表面特定蛋白质融合并展示于其表面,构建蛋白质或抗体库,并从中筛选特异蛋白质或抗体的基因工程技术。介绍这一技术的原理、相关展示系统以及在蛋白质相互作用的研究,抗体及疫苗的制备、多肽药物的研制等方面的应用潜力和独特的优点。